Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011252977> ?p ?o ?g. }
- W2011252977 endingPage "4405" @default.
- W2011252977 startingPage "4398" @default.
- W2011252977 abstract "Abstract Purpose: Androgen ablation-refractory prostate cancer patients (stage D3) develop painful bone metastases and limited responsiveness to conventional therapies, hence the lack of universally accepted “gold standard” treatment for this poor prognosis clinical setting. We tested the safety and efficacy in stage D3 patients of the combination hormonal therapy, which combines administration of somatostatin analog and dexamethasone with standard androgen ablation monotherapy (luteinizing-hormone releasing-hormone analog or orchiectomy). Experimental Design: Thirty eight patients with stage D3 prostate cancer (mean age 71.8 ± 5.9 years) continued receiving androgen ablation therapy in combination with oral dexamethasone (4 mg daily for the 1st month of treatment, tapered down to 1 mg daily by the 4th month, with 1 mg daily maintenance dose thereafter) and somatostatin analog (20 mg octreotide i.m. injections every 28 days). Results: Twenty-three of 38 patients (60.5%) receiving this combination regimen had partial responses [PR, ≥50% prostate-specific antigen (PSA) decline], 9 (21.1%) had stable disease, and 7 (18.4%) had progressive disease. In 47.7% (18 of 38) of patients, their serum PSA levels decreased with treatment but did not return to their respective baselines until the end of follow-up (or death from non-prostate cancer-related causes). The median time-to-return to baseline PSA was 12 months (95% CI, 7–17 months), median progression-free survival was 7 months (95% CI, 4.5–9.5 months), median overall survival was 14 months (95% CI, 10.7–17.4 months), and median prostate cancer-specific overall survival (defined as time from onset of combination therapy until prostate cancer-related death) was 16.0 months (95% CI, 11.9–20.1 months). All patients reported significant and durable improvement of bone pain and performance status (for a median duration of 14 months; 95% CI, 9–19 months), without major treatment-related side effects. We observed a statistically significant (P < 0.01) reduction in serum insulin-like growth factor-1 levels at response to the combination therapy. T levels remained suppressed within castration levels at baseline and throughout therapy, including relapse. Conclusion: The combination therapy of dexamethasone plus somatostatin analog and standard androgen ablation manipulation produces objective clinical responses and symptomatic improvement in androgen ablation-refractory refractory prostate cancer patients." @default.
- W2011252977 created "2016-06-24" @default.
- W2011252977 creator A5009183154 @default.
- W2011252977 creator A5012712111 @default.
- W2011252977 creator A5028413427 @default.
- W2011252977 creator A5038410281 @default.
- W2011252977 creator A5057497640 @default.
- W2011252977 creator A5078875546 @default.
- W2011252977 creator A5088048070 @default.
- W2011252977 date "2004-07-01" @default.
- W2011252977 modified "2023-09-23" @default.
- W2011252977 title "Combination of Somatostatin Analog, Dexamethasone, and Standard Androgen Ablation Therapy in Stage D3 Prostate Cancer Patients with Bone Metastases" @default.
- W2011252977 cites W1972281874 @default.
- W2011252977 cites W1974223241 @default.
- W2011252977 cites W1979026224 @default.
- W2011252977 cites W1984749582 @default.
- W2011252977 cites W1985316433 @default.
- W2011252977 cites W1987254959 @default.
- W2011252977 cites W1990084044 @default.
- W2011252977 cites W1995106518 @default.
- W2011252977 cites W2008106678 @default.
- W2011252977 cites W2011679916 @default.
- W2011252977 cites W2027394747 @default.
- W2011252977 cites W2041109673 @default.
- W2011252977 cites W2056144498 @default.
- W2011252977 cites W2056628930 @default.
- W2011252977 cites W2058825665 @default.
- W2011252977 cites W2067565371 @default.
- W2011252977 cites W2074362305 @default.
- W2011252977 cites W2083143012 @default.
- W2011252977 cites W2086725308 @default.
- W2011252977 cites W2093221289 @default.
- W2011252977 cites W2102303758 @default.
- W2011252977 cites W2139474929 @default.
- W2011252977 cites W2155679349 @default.
- W2011252977 cites W2155801403 @default.
- W2011252977 cites W2165901065 @default.
- W2011252977 cites W2168654868 @default.
- W2011252977 cites W2169702768 @default.
- W2011252977 cites W2334850327 @default.
- W2011252977 cites W4252564070 @default.
- W2011252977 cites W61595050 @default.
- W2011252977 doi "https://doi.org/10.1158/1078-0432.ccr-04-0077" @default.
- W2011252977 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15240528" @default.
- W2011252977 hasPublicationYear "2004" @default.
- W2011252977 type Work @default.
- W2011252977 sameAs 2011252977 @default.
- W2011252977 citedByCount "50" @default.
- W2011252977 countsByYear W20112529772012 @default.
- W2011252977 countsByYear W20112529772013 @default.
- W2011252977 countsByYear W20112529772015 @default.
- W2011252977 countsByYear W20112529772017 @default.
- W2011252977 countsByYear W20112529772020 @default.
- W2011252977 countsByYear W20112529772022 @default.
- W2011252977 countsByYear W20112529772023 @default.
- W2011252977 crossrefType "journal-article" @default.
- W2011252977 hasAuthorship W2011252977A5009183154 @default.
- W2011252977 hasAuthorship W2011252977A5012712111 @default.
- W2011252977 hasAuthorship W2011252977A5028413427 @default.
- W2011252977 hasAuthorship W2011252977A5038410281 @default.
- W2011252977 hasAuthorship W2011252977A5057497640 @default.
- W2011252977 hasAuthorship W2011252977A5078875546 @default.
- W2011252977 hasAuthorship W2011252977A5088048070 @default.
- W2011252977 hasBestOaLocation W20112529771 @default.
- W2011252977 hasConcept C121608353 @default.
- W2011252977 hasConcept C126322002 @default.
- W2011252977 hasConcept C126894567 @default.
- W2011252977 hasConcept C141071460 @default.
- W2011252977 hasConcept C143998085 @default.
- W2011252977 hasConcept C2776235491 @default.
- W2011252977 hasConcept C2777911890 @default.
- W2011252977 hasConcept C2780192828 @default.
- W2011252977 hasConcept C2781406297 @default.
- W2011252977 hasConcept C2781413609 @default.
- W2011252977 hasConcept C71315377 @default.
- W2011252977 hasConcept C71924100 @default.
- W2011252977 hasConcept C90924648 @default.
- W2011252977 hasConceptScore W2011252977C121608353 @default.
- W2011252977 hasConceptScore W2011252977C126322002 @default.
- W2011252977 hasConceptScore W2011252977C126894567 @default.
- W2011252977 hasConceptScore W2011252977C141071460 @default.
- W2011252977 hasConceptScore W2011252977C143998085 @default.
- W2011252977 hasConceptScore W2011252977C2776235491 @default.
- W2011252977 hasConceptScore W2011252977C2777911890 @default.
- W2011252977 hasConceptScore W2011252977C2780192828 @default.
- W2011252977 hasConceptScore W2011252977C2781406297 @default.
- W2011252977 hasConceptScore W2011252977C2781413609 @default.
- W2011252977 hasConceptScore W2011252977C71315377 @default.
- W2011252977 hasConceptScore W2011252977C71924100 @default.
- W2011252977 hasConceptScore W2011252977C90924648 @default.
- W2011252977 hasIssue "13" @default.
- W2011252977 hasLocation W20112529771 @default.
- W2011252977 hasLocation W20112529772 @default.
- W2011252977 hasOpenAccess W2011252977 @default.
- W2011252977 hasPrimaryLocation W20112529771 @default.
- W2011252977 hasRelatedWork W1980188241 @default.
- W2011252977 hasRelatedWork W1992657261 @default.
- W2011252977 hasRelatedWork W2038565121 @default.